Harłoziñska A, Bar J K, Wenderski R, Bebenek M
Department of Tumor Immunology, Wrocław University of Medicine, Poland.
In Vivo. 1996 Mar-Apr;10(2):217-22.
The expression of c-erbB-2 oncoprotein, epidermal growth factor receptor (EGFR) and estrogen receptor (ER) was evaluated by the immunoperoxidase technique (PAP) in ductal breast carcinomas. The relationship between these cell growth regulatory factors was considered and compared with tumor grading, tumor size, lymph node involvement and age of patients. Stratifying of patients on the basis of c-erbB-2, EGFR and ER status indicated that the combination of c-erbB-2 overexpression accompanied by high EGFR value and undetectable ER, identified poorly differentiated tumors and patients with high incidence of axillary lymph node metastases, while high EGFR expression and negative c-erbB-2 staining was connected only with poor tumor grade. The undetectability of molecular markers was associated with higher histological grade and lack of lymph node involvement. Our results indicate that the comparison of c-erbB-2, EGFR and ER status seems to be a powerful tool in discriminating breast carcinomas with different biological phenotypes.
采用免疫过氧化物酶技术（PAP法）评估乳腺导管癌中c-erbB-2癌蛋白、表皮生长因子受体（EGFR）和雌激素受体（ER）的表达情况。分析这些细胞生长调节因子之间的关系，并与肿瘤分级、肿瘤大小、淋巴结受累情况及患者年龄进行比较。根据c-erbB-2、EGFR和ER状态对患者进行分层分析，结果显示，c-erbB-2过表达伴高EGFR值且ER检测不到的情况，提示肿瘤分化差且腋窝淋巴结转移发生率高；而高EGFR表达且c-erbB-2染色阴性仅与肿瘤分级差有关。分子标志物检测不到与较高的组织学分级及无淋巴结受累相关。我们的结果表明，比较c-erbB-2、EGFR和ER状态似乎是鉴别具有不同生物学表型乳腺癌的有力工具。
